Lithium Carbonate 300 mg/1 TABLET, EXTENDED RELEASE
FDA Drug Information
Indications & Usage
INDICATIONS Lithium carbonate extended-release tablets is indicated in the treatment of manic episodes of Bipolar Disorder. Bipolar Disorder, Manic (DSM-IV) is equivalent to Manic Depressive illness, Manic, in the older DSM-II terminology. Lithium carbonate extended-release tablets is also indicated as a maintenance treatment for individuals with a diagnosis of Bipolar Disorder. Maintenance therapy reduces the frequency of manic episodes and diminishes the intensity of those episodes which may o…
Important Warnings
WARNINGS Lithium Toxicity The toxic concentrations for lithium (≥1.5 mEq/L) are close to the therapeutic range (0.8 to 1.2 mEq/L). Some patients abnormally sensitive to lithium may exhibit toxic signs at serum concentrations that are considered within the therapeutic range (see BOXED WARNING and DOSAGE AND ADMINISTRATION ). Lithium may take up to 24 hours to distribute into brain tissue, so occurr…
Source: FDA. For professional use only. Not a substitute for prescribing information.
Other Lithium Carbonate NDC Codes
Wholesale and compliance resources
Order NDC 64980-0205-01 at Wholesale
Create a free Premier Pharma account to unlock live wholesale pricing and place orders with same-day fulfillment and full DSCSA T2 documentation (TI + TS).